Company Analysis

Insight Molecular Diagnostics Inc. (IMDX)

Nasdaq: IMDX · In Vitro & In Vivo Diagnostic Substances · Nashville, TN · filing with the SEC since 2015
Grade4.7
◀ Past 3.6● Present 2.9▶ Future 7.1
1 est.

Who runs Insight Molecular Diagnostics Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Riggs Josh
CEO and President. First filing Dec 2022, latest Mar 30, 2026, 1 filing in all.
Officers reporting now
3
of 6 people with a filing in the last fifteen months
Directors reporting now
3
28 people on the record since 2015
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Riggs JoshCEO and PresidentDec 2022Mar 30, 2026none
James Andrea S.Chief Financial OfficerJun 2024Mar 30, 2026none
Liu James YangVP ACCT, Cntlr, Treasurer, PAOSep 2022Mar 30, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Arno AndrewdirectorDec 2015Jul 6, 2026none
Last Andrew J.directorDec 2015Jul 6, 2026none
Silverman LoudirectorDec 2022Jul 6, 2026none
Owners of more than 10% of a classsales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bradsher Neal C10% ownerSep 2016Apr 27, 2026none
Broadwood Capital Inc10% ownerSep 2016Apr 27, 2026none
Broadwood Partners, L.P.10% ownerSep 2016Apr 27, 2026none
Earlier names on the record26, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton IMDX · research, not advice